



HAL
open science

Lack of artemisinin resistance in *Plasmodium falciparum* in northwest Benin after 10 years of use of artemisinin-based combination therapy

Aurore Ogouyemi-Hounto, Georgia Damien, Awa Bineta Deme, Nicaise T Ndam, Constance Assouhou, Didier Tchoulin, Atika Mama, Virgile Olivier Hounkpe, Jules Doumitou Moutouama, Franck Remoue, et al.

► To cite this version:

Aurore Ogouyemi-Hounto, Georgia Damien, Awa Bineta Deme, Nicaise T Ndam, Constance Assouhou, et al.. Lack of artemisinin resistance in *Plasmodium falciparum* in northwest Benin after 10 years of use of artemisinin-based combination therapy. *Parasite*, 2016, 23, pp.28. 10.1051/parasite/2016028 . hal-02003180

HAL Id: hal-02003180

<https://hal.umontpellier.fr/hal-02003180v1>

Submitted on 1 Feb 2019

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Lack of artemisinin resistance in *Plasmodium falciparum* in northwest Benin after 10 years of use of artemisinin-based combination therapy

Aurore Ogouyèmi-Hounto^{1,2,*}, Georgia Damien³, Awa Bineta Deme⁴, Nicaise T. Ndam⁵, Constance Assouhou³, Didier Tchonlin², Atika Mama², Virgile Olivier Hounkpe⁶, Jules Doumitou Moutouama⁷, Franck Remoué³, Daouda Ndiaye⁴, and Dorothée Kindé Gazard^{1,2}

¹ Unité d'Enseignement et de Recherche en Parasitologie – Mycologie/Faculté des Sciences de la Santé; 01 BP 188 Cotonou, Bénin

² Laboratoire du centre de lutte intégrée contre le paludisme; 01 BP 188 Cotonou, Bénin

³ Institut de Recherche pour le Développement. UMR 224-MIVEGEC; 08 BP 841 Cotonou, Bénin

⁴ Laboratory of Parasitology Mycology, Aristide le Dantec Hospital, BP 16477 Dakar, Senegal

⁵ UMR 216 MERIT-IRD Parasitology Department Noguchi Memorial Institute for Medical Research College of Health Sciences, University of Ghana, P.O. Box LG581 Legon, Accra, Ghana

⁶ Centre de santé de la Commune de Djougou, 02 BP 681 Porto Novo, Benin

⁷ Centre de santé de la Commune de Coby, BP 40 Tanguéta, Bénin

Received 26 March 2016, Accepted 28 June 2016, Published online 21 July 2016

Abstract – Aim: In Benin, artemisinin-based combination therapy (ACT) has been recommended as the first-line treatment for uncomplicated *Plasmodium falciparum* malaria since 2004. The emergence in Southeast Asia of parasites that are resistant to artemisinins poses a serious threat to global control of this disease. The presence of artemisinin resistance genotypes in parasite populations in Benin is currently unknown. The present study investigated the prevalence of relevant *K13-propeller* gene polymorphisms in parasite isolates from the north-western region of Benin. **Method:** *Plasmodium falciparum* isolates were collected from children with a confirmed diagnosis of malaria aged 6 months to 5 years in two towns, Coby and Djougou, in the north-western part of Benin. The study was conducted during the rainy season from July to November 2014 in local health facilities. The *K13-propeller* gene was amplified in parasite isolates using nested PCR and subsequently sequenced. **Results:** A total of 108 children were recruited into the study. The efficiency of amplification reactions was 72% (78/108). The propeller domain of the *K13* gene was successfully sequenced in 78 *P. falciparum* isolates; all of them were wild type with no polymorphisms detectable. **Conclusion:** The absence of mutations in the *K13* gene indicates that *P. falciparum* parasite populations in the study area are still fully susceptible to artemisinins.

Key words: *Plasmodium falciparum*, Malaria, Resistance, Artemisinin, *K13* propeller, Benin.

Résumé – Absence de résistance à l'artémisinine chez *Plasmodium falciparum* dans le Nord-ouest du Bénin après dix ans d'utilisation de combinaisons thérapeutiques à base de dérivés d'artémisinine. Contexte : Au Bénin, depuis 2004, les combinaisons thérapeutiques à base d'artémisinine ont été recommandées comme traitement de première intention du paludisme à *Plasmodium falciparum* non compliqué. L'émergence en Asie du Sud-Est de parasites qui sont résistants à l'artémisinine pose une menace sérieuse pour la lutte mondiale contre cette maladie. La présence de génotypes de résistance à l'artémisinine dans les populations de parasites au Bénin est actuellement inconnue. Cette étude a étudié la prévalence des polymorphismes du gène *K13-propeller* chez des parasites isolés de la région nord-ouest du Bénin. **Méthodes :** Les isolats de *Plasmodium falciparum* ont été recueillis auprès d'enfants ayant un diagnostic confirmé de paludisme, âgés de 6 mois à 5 ans, dans deux villes, Coby et Djougou, dans la partie nord-ouest du Bénin. L'étude a été menée pendant la saison des pluies de juillet à novembre 2014 dans les établissements de santé locaux. Le gène *K13-propeller* a été amplifié dans les isolats de parasites par PCR imbriquée, et ensuite séquencé. **Résultats :** Un total de 108 enfants a été recruté dans l'étude.

*Corresponding author: aurorefel@yahoo.fr

L'efficacité des réactions d'amplification a été de 72 % (78/108). Le gène *K13-propeller* a été séquencé avec succès dans 78 isolats de *P. falciparum* ; tous étaient de type sauvage sans polymorphisme détectable.

Conclusion : l'absence de mutations dans le gène *K13* indique que les populations du parasite *P. falciparum* dans la zone d'étude sont encore pleinement sensibles aux artémisinines.

Introduction

Artemisinin-based combination therapies are recommended by the World Health Organization (WHO) as first-line treatment for uncomplicated falciparum malaria in all areas in which malaria is endemic [32]. In 2004, as a result of high failure rates of treatment recorded with chloroquine and sulphadoxine-pyrimethamine (unpublished data from the National Malaria Control Programme), the Beninese National Malaria Control Programme implemented artemisinin-based combination therapy (ACT) as the first-line treatment for uncomplicated malaria. The artemether-lumefantrine combination was thus deployed throughout the country in health facilities.

Currently, the different ACTs in use remain highly effective for the treatment of malaria in Africa, as demonstrated both by rapid parasite clearance and low rates of recrudescence after therapy in clinical trials, as well as by the high rates of sensitivity of clinical isolates *ex vivo* [3, 16, 19, 27, 31, 35]. The first clinical cases of artemisinin resistance in western Cambodia were reported in 2008 [21], and *Plasmodium falciparum* with reduced *in vivo* susceptibility to artesunate was reported in 2009 [8, 9]. Emergence of resistance was subsequently reported in neighbouring regions [2, 11, 25]. These recent developments have grave implications for public health, since artemisinin derivatives are the mainstay of anti-malarial treatment worldwide. Hence the spread of ACT resistance could be catastrophic for malaria control and elimination efforts around the globe.

Despite the absence, thus far, of mutations associated with artemisinin resistance in *P. falciparum* isolates from different areas of sub-Saharan Africa [7, 20], previous experience with the spread of chloroquine and sulphadoxine-pyrimethamine resistant parasites from Asia to Africa [18, 33] demonstrates that the spread of drug resistance is likely, and that vigilant surveillance for resistant parasites is warranted. Recently, mutations in the propeller domain of the *K13* gene were identified as candidate molecular markers of artemisinin resistance associated with slow parasite clearance rates [1, 6, 17, 28]. These associations indicate that mutations in the *K13 propeller* (especially C580Y, R539T and Y439H) are important determinants of artemisinin resistance. These markers could therefore serve as a tool to monitor resistance to ACT. Although ACT remains highly efficacious for the treatment of falciparum malaria, and delayed parasite clearance after ACT has not been noted in Benin [15, 22], the molecular epidemiology of artemisinin resistance genotypes in Benin parasite populations is unknown. The aim of the study

described here was to characterise the variability of the *K13* gene for the first time in Benin.

Methods

Study site

The study was conducted in Benin during the rainy season between July and November 2014, in two towns named Djougou, situated 450 km from Cotonou (the economic capital), and Cobly, 643 km from Cotonou. At the two sites, malaria transmission occurs from May to November during the rainy season. *P. falciparum* is the predominant parasite species transmitted by *Anopheles gambiae* (85%) and *An. arabiensis* (15%) [34]. The prevalence of *P. falciparum* infection in the general population was 19.1% in Djougou and 18% in Cobly (unpublished data).

Patients, sample collection and laboratory procedures

Plasmodium falciparum isolates were obtained from children diagnosed with malaria who had lived in the area of the study sites for more than a period of 6 months and had not travelled during the previous month. Children visiting the health facilities in the study area, aged 6 months to 5 years, and who met the criteria below were enrolled in the study: (i) fever (axillary temperature ≥ 37.5 °C) or a history of fever within the past 48 h, (ii) *P. falciparum* mono-infection with parasite density $\geq 1,000$ asexual forms per microlitre, identified by microscopy on blood smears; and (iii) written informed consent from parents. Venous blood from children fulfilling the above criteria was collected. Thick and thin blood smears were prepared, stained with 10% Giemsa and examined to determine *P. falciparum* density and to confirm mono-infection by *P. falciparum*. All thick blood smears were examined against 500 leucocytes. Parasite densities were recorded as the number of parasites/ μL of blood, assuming an average leucocyte count of 8,000/ μL of blood. All slides were read in the laboratories of the health centres, with external quality control performed on 10% of the negative slides and all positives in the reference Parasitology Laboratory of the *Centre National Hospitalo-Universitaire* in Cotonou. Evaluation of *K13-propeller* polymorphisms was performed using the same venous blood sample used for diagnostic analysis stored as spots on filter paper. All malaria-infected patients, based on microscopy results, were treated with standard doses of

artemether/lumefantrine according to the national malaria treatment policy based on ACT.

Analysis of *Plasmodium falciparum* isolates

Parasite DNA was extracted from filter paper using the Chelex method [26]. The propeller domain of the *K13* gene was amplified by nested PCR using the following primers: for the primary PCR (K13_PCR_F 5'-G GGAATCTGGTGG-TAACAGC-3' and K13_PCR_R 5'-C GGAGTGAC-CAAATCTGGGA-3') and for the nested PCR (K13_N1_F 5'-GCCTTGTTGAAAGAAGCAGA-3' and K13_N1_R 5'-GCCAAGCTGCCATTCATTTG-3'). The reaction volume and amplification programme used were reported previously [1]. Amplified products were bi-directionally sequenced by Sanger sequencing using BigDye® v3.1 from ThermoFisher Scientific by Beckman Coulter Genomics. The sequence reactions were then run on an ABI3730xl following the manufacturer's protocols. The propeller domain of the *K13* sequence data for single nucleotide polymorphisms (SNPs) was analysed using Geneious software (www.geneious.com). A cut-off of quality score HQ > 30% (the percentage of untrimmed bases that are high quality) was applied to all sequences. Sequences were assembled using the *de novo* assembly method and aligned to the reference *K13* annotated *Plasmodium falciparum* 3D7 (PF3D7-1343700). The polymorphism search was limited to inside CDS sequences. A search was performed for the mutations described in Asia and in the previous study [13, 14, 29].

Ethical approval: The study obtained the ethical approval of the National Ethics Committee for Health Research of Benin.

Results

During the study period, a total of 225 potentially eligible patients were screened for participation in the study. Following application of inclusion criteria, a total of 108 participants were enrolled in the study. Children's ages ranged from 6 months to 5 years (mean age: 31.6 ± 0.4 months). Parasite density ranged from 1,028 to 192,715 parasites/ μ L with a geometric mean density of 16,562 [9,909; 27,681]. Parasite DNA from the 108 *P. falciparum* isolates was analysed for *pfK13* genes. The efficiency of amplification reactions was 72.2% (78/108).

Polymorphism of the *K13* propeller

The propeller domain of the *K13* gene was successfully sequenced in 78 *P. falciparum* isolates. After alignment with PF3D7-1343700, all the strains were found to be wild type having no polymorphism previously found in the *K13* gene.

Discussion

In Benin, ACT was introduced as the first-line treatment for uncomplicated *P. falciparum* malaria in 2004. Although this

treatment remains highly efficacious, it is important to monitor the potential presence of artemisinin-resistant *P. falciparum* parasite populations. The fact that only 72% of included samples were genotyped could be explained by the sensitivity of the PCR method used, because we did not analyse samples with low parasitaemia.

In this study, we did not find any mutation in the propeller part of the gene, as was the case in the Chatterie study in India [5]. Clinical artemisinin resistance is defined as a reduced parasite clearance rate, expressed as an increased parasite clearance half-life or a persistence of microscopically detectable parasites on the third day of ACT. The half-life parameter correlates strongly with results from the *in vitro* ring-stage survival assay. The absence of mutations in the *K13* gene of parasite strains isolated in Benin confirms the results of the therapeutic efficacy tests, conducted at the same study sites, where adequate clinical and parasitological response was 100% after PCR correction [22]. Thus, after 10 years of ACT use, no polymorphisms have appeared in the *K13* gene, suggesting that *P. falciparum* populations in the north-western part of Benin are still effectively susceptible to artemisinin. However, a larger sample size with extension into other parts of the country, including the south where drug pressure is higher [23], would allow us to draw better conclusions in this context. Artemisinin resistance, with delayed clearance of parasites after treatment with artemisinin monotherapy or artemisinin combination therapies (ACTs), is of great concern but has not yet been documented in sub-Saharan Africa, where speed of clearance of parasites after treatment with ACTs has generally been within the expected range [3, 10, 24, 31]. Small numbers of parasites with *K13*-propeller gene polymorphisms have been described in some countries in Africa, but importantly these were not the mutations previously associated with drug resistance in Southeast Asia [7, 20, 30]. The absence thus far of *K13* resistance-associated mutants from Southeast Asia in Africa is promising, but continuous surveillance for the emergence of resistance should be implemented to enable early detection. The use of molecular markers such as *K13* mutations is nowadays a cornerstone of malaria surveillance programmes, but potential differences between African and Asian *K13*-mutant parasites should be taken into account. The polymorphisms associated with artemisinin resistance in *P. falciparum* in Southeast Asia are not present in sub-Saharan Africa, but numerous *K13*-propeller coding polymorphisms have been documented in Africa [12–14, 24, 29]. Although their distributions do not support a widespread selective sweep for an artemisinin-resistant phenotype, the impact of these mutations on artemisinin susceptibility is unknown and will require further characterisation. Longitudinal studies conducted in Kenya [4, 20] showed that parasites from only one of 32 patients carried a mutation (at codon 578 (A578S)) in the propeller region of the *pfK13* gene, despite evidence of longer than normal parasite persistence in over 30% of children. To identify *K13* polymorphisms that affect artemisinin sensitivity in Africa, clinical trials should be supplemented with *in vitro* and molecular studies, providing additional data to strengthen confidence that observed mutations are associated with slowed parasite clearance.

Conclusion

In this study, the absence of mutations in the *K13*-propeller gene suggests that artemisinin resistance is not a problem in Benin. However, similar studies from different parts of the country with a larger number of samples will be helpful to ascertain the emergence of artemisinin resistance, if any. In addition, routine monitoring and surveillance, as recommended by the WHO global plan for artemisinin resistance containment, should be continuously strengthened. Moreover, this study contributes to the ongoing surveillance of suspected artemisinin resistance parasites in Africa by providing baseline data on *K13*-propeller mutations in Benin.

Conflict of interest

The authors declare no conflict of interest in relation with this paper.

Acknowledgements. We are grateful to the children who participated in the study, as well as to their mothers. We are pleased to thank caregivers from Djougou and Coby health services. This work was integrated into the PALEVALUT project, funded by the 5% – Expertise France Initiative. This funding contributed to data collection, laboratory testing and payment of investigators.

References

- Ariey F, Witkowski B, Amaratunga C, Beghain J, Langlois AC, Khim N, Kim S, Duru V, Bouchier C, Ma L, Lim P, Leang R, Duong S, Sreng S, Suon S, Chuor CM, Bout DM, Ménard S, Rogers WO, Genton B, Fandeur T, Miotto O, Ringwald P, Le Bras J, Berry A, Barale JC, Fairhurst RM, Benoit-Vical F, Mercereau-Puijalon O, Ménard D. 2014. A molecular marker of artemisinin resistant *Plasmodium falciparum*. *Nature*, 505, 50–55.
- Ashley EA, Dhorda M, Fairhurst RM, Amaratunga C, Lim P, Suon S, Sreng S, Anderson JM, Mao S, Sam B, Sopha C, Chuor CM, Nguon C, Sovannaroeth S, Pukrittayakamee S, Jittamala P, Chotivanich K, Chutasmit K, Suchatsoonthorn C, Runchaoren R, Hien TT, Thuy-Nhien NT, Thanh NV, Phu NH, Htut Y, Han KT, Aye KH, Mokuolu OA, Olaosebikan RR, Folaranmi OO, Mayxay M, Khanthavong M, Hongvanthong B, Newton PN, Onyamboko MA, Fanello CI, Tshefu AK, Mishra N, Valecha N, Phyo AP, Nosten F, Yi P, Tripura R, Borrmann S, Bashraheil M, Peshu J, Faiz MA, Ghose A, Hossain MA, Samad R, Rahman MR, Hasan MM, Islam A, Miotto O, Amato R, MacInnis B, Stalker J, Kwiatkowski DP, Bozdech Z, Jeeyapant A, Cheah PY, Sakulthaew T, Chalk J, Intharabut B, Silamut K, Lee SJ, Vihokhern B, Kunasol C, Imwong M, Tarning J, Taylor WJ, Yeung S, Woodrow CJ, Flegg JA, Das D, Smith J, Venkatesan M, Plowe CV, Stepniewska K, Guerin PJ, Dondorp AM, Day NP, White NJ. 2014. Spread of artemisinin resistance in *Plasmodium falciparum* malaria. *New England Journal of Medicine*, 371, 411–423.
- Assefa A, Kassa M, Tadese G, Mohamed H, Anmut A, Mengsha T. 2010. Therapeutic efficacy of Artemether/Lumefantrine (Coartem®) against *Plasmodium falciparum* in Kersa, South West Ethiopia. *Parasites & Vectors*, 3, 2–9.
- Beshir KB, Sutherland CJ, Sawa P, Drakeley CJ, Okell L, Mweresa CK, Omar SA, Shekalaghe SA, Kaur H, Ndaro A, Chilongola J, Schallig HD, Sauerwein RW, Hallett RL, Bousema T. 2013. Residual *Plasmodium falciparum* parasitemia in Kenyan children after artemisinin-combination therapy is associated with increased transmission to mosquitoes and parasite recurrence. *Journal of Infectious Diseases*, 208, 2017–2024.
- Chatterie M, Ganguly S, Saha P, Bankura B, Basu N, Das M, Guha SK, Maji AK. 2015. No polymorphism in *Plasmodium falciparum* K13 propeller gene in clinical isolates from Kolkata, India. *Journal of Pathogens*, 2015, 374354.
- Cheeseman IH, Miller BA, Nair S, Nkhoma S, Tan A, Tan JC, Al Saai S, Phyo AP, Moo CL, Lwin KM, McGready R, Ashley E, Imwong M, Stepniewska K, Yi P, Dondorp AM, Mayxay M, Newton PN, White NJ, Nosten F, Ferdig MT, Anderson TJ. 2012. A major genome region underlying artemisinin resistance in malaria. *Science*, 336, 79–82.
- Cooper RA, Conrad MD, Watson QD, Huezo SJ, Ninsiima H, Tumwebaze P, Nsohya SL, Rosenthal PJ. 2015. Lack of artemisinin resistance in *Plasmodium falciparum* in Uganda based on parasitological and molecular assays. *Antimicrobial Agents and Chemotherapy*, 59, 5061–5064.
- Dondorp AM, Fairhurst RM, Slutsker L, Macarthur JR, Breman JG, Guerin PJ, Wellems TE, Ringwald P, Newman RD, Plowe CV. 2011. The threat of artemisinin-resistant malaria. *New England Journal of Medicine*, 365, 1073–1075.
- Dondorp AM, Nosten F, Yi P, Das D, Phyo AP, Tarning J, Lwin KM, Ariey F, Hanpithakpong W, Lee SJ, Ringwald P, Silamut K, Imwong M, Chotivanich K, Lim P, Herdman T, An SS, Yeung S, Singhasivanon P, Day NP, Lindegardh N, Socheat D, White NJ. 2009. Artemisinin resistance in *Plasmodium falciparum* malaria. *New England Journal of Medicine*, 361, 455–467.
- Hamainza B, Masaninga F, Moonga H, Mwenda M, Chanda-Kapata P, Chalwe V, Chanda E, Kamuliwo M, Babaniyi OA. 2014. Therapeutic efficacy of artemether–lumefantrine on treatment of uncomplicated *Plasmodium falciparum* mono-infection in an area of high malaria transmission in Zambia. *Malaria Journal*, 13, 430.
- Hien TT, Thuy-Nhien NT, Phu NH, Boni MF, Thanh NV, Nha-Ca NT, Thai LH, Thai CQ, Toi PV, Thuan PD, Long LT, Dong LT, Merson L, Dolecek C, Stepniewska K, Ringwald P, White NJ, Farrar J, Wolbers M. 2012. In vivo susceptibility of *Plasmodium falciparum* to artesunate in Binh Phuoc Province, Vietnam. *Malaria journal*, 11, 355.
- Huang B, Deng C, Yang T, Xue L, Wang Q, Huang S, Su XZ, Liu Y, Zheng S, Guan Y, Xu Q, Zhou J, Yuan J, Bacar A, Abdallah KS, Attoumane R, Mliva AMSA, Zhong Y, Lu F, Song J. 2015. Polymorphisms of the artemisinin resistant marker (K13) in *Plasmodium falciparum* parasite populations of Grande Comore Island 10 years after artemisinin combination therapy. *Parasites & Vectors*, 8, 634.
- Isozumi R, Uemura H, Kimata I, Ichinose Y, Logedi J, Omar AH, Kaneko A. 2015. Novel mutations in K13 propeller gene of artemisinin-resistant *Plasmodium falciparum*. *Emerging Infectious Diseases*, 21, 490–492.
- Kamau E, Campino S, Amenga-Etego L, Drury E, Ishengoma D, Johnson K, Mumba D, Kekre M, Yavo W, Mead D, Bouyou-Akotet M, Apinjoh T, Golassa L, Randrianarivelojosa M, Andagalu B, Maiga-Ascofare O, Amambua-Ngwa A, Tindana P,

- Ghansah A, MacInnis B, Kwiatkowski D, Djimde AA. 2015. K13-propeller polymorphisms in *Plasmodium falciparum* parasites from sub-Saharan Africa. *Journal of Infectious Diseases*, 211, 1352–1355.
15. Kinde Gazard D, Ogouyèmi-Hounto A, Capo-Chichi L, Gbaguidi J, Massougbdji A. 2012. Essai clinique randomisé comparant l'efficacité et la tolérance de la combinaison Artémisinine–Naphthoquine (Arco[®]) et Artémèther–Luméfantine (Coartem[®]) dans le traitement du paludisme simple au Bénin. *Bulletin de la Société de Pathologie Exotique*, 105, 208–214.
 16. Maiga AW, Fofana B, Sagara I, Dembele D, Dara A, Traore OB, Toure S, Sanogo K, Dama S, Sidibe B, Kone A, Thera MA, Plowe CV, Doumbo OK, Djimde AA. 2012. No evidence of delayed parasite clearance after oral artesunate treatment of uncomplicated falciparum malaria in Mali. *American Journal of Tropical Medicine and Hygiene*, 87, 23–28.
 17. Miotto O, Almagro-Garcia J, Manske M, Macinnis B, Campino S, Rockett KA, Amaratunga C, Lim P, Suon S, Sreng S, Anderson JM, Duong S, Nguon C, Chuor CM, Saunders D, Se Y, Lon C, Fukuda MM, Amenga-Etego L, Hodgson AV, Asoala V, Imwong M, Takala-Harrison S, Nosten F, Su XZ, Ringwald P, Ariey F, Dolecek C, Hien TT, Boni MF, Thai CQ, Amambua-Ngwa A, Conway DJ, Djimde AA, Doumbo OK, Zongo I, Ouedraogo JB, Alcock D, Drury E, Auburn S, Koch O, Sanders M, Hubbart C, Maslen G, Ruano-Rubio V, Jyothi D, Miles A, O'Brien J, Gamble C, Oyola SO, Rayner JC, Newbold CI, Berriman M, Spencer CC, McVean G, Day NP, White NJ, Bethell D, Dondorp AM, Plowe CV, Fairhurst RM, Kwiatkowski D. 2013. Multiple populations of artemisinin-resistant *Plasmodium falciparum* in Cambodia. *Nature Genetics*, 45, 648–655.
 18. Mita T, Venkatesan M, Ohashi J, Culleton R, Takahashi N, Tsukahara T, Ndounga M, Dysoley L, Endo H, Hombhanje F, Ferreira MU, Plowe CV, Tanabe K. 2011. Limited geographical origin and global spread of sulfadoxine-resistant dhps alleles in *Plasmodium falciparum* populations. *Journal of Infectious Diseases*, 204, 1980–1988.
 19. Muhindo MK, Kakuru A, Jagannathan P, Talisuna A, Osilo E, Orukan F, Arinaitwe E, Tappero JW, Kaharuza F, Kanya MR, Dorsey G. 2014. Early parasite clearance following artemisinin-based combination therapy among Ugandan children with uncomplicated *Plasmodium falciparum* malaria. *Malaria Journal*, 13, 32–37.
 20. Muwanguzi J, Henriques G, Sawa P, Bousema T, Sutherland CJ, Beshir KB. 2016. Lack of K13 mutations in *Plasmodium falciparum* persisting after artemisinin combination therapy treatment of Kenyan children. *Malaria Journal*, 15, 36.
 21. Noedl H, Se Y, Schaecher K, Smith BL, Socheat D, Fukuda MM. 2008. Evidence of artemisinin-resistant malaria in western Cambodia. *New England Journal of Medicine*, 359, 2619–2620.
 22. Ogouyèmi-Hounto A, Azandosessi C, Lawani S, Damien G, SissintoSavi de Tove Y, Remoue F, KindeGazard D. 2016. Therapeutic efficacy of artemether–lumefantrine for the treatment of uncomplicated falciparum malaria in northwest Benin. *Malaria Journal*, 15, 37.
 23. Ogouyèmi-Hounto A, Ndam NK, Fadégnon G, Azagnandji C, Bello M, Moussiliou A, Chippaux JP, KindeGazard D, Massougbdji A. 2013. Low prevalence of the molecular markers of *Plasmodium falciparum* resistance to chloroquine and sulphadoxine/pyrimethamine in asymptomatic children in Northern Benin. *Malaria Journal*, 12, 413.
 24. Ouattara A, Kone A, Adams M, Fofana B, Maiga AW, Hampton S, Coulibaly D, Thera MA, Diallo N, Dara A, Sagara I, Gil JP, Bjorkman A, Takala-Harrison S, Doumbo OK, Plowe CV, Djimde AA. 2015. Polymorphisms in the K13-propeller gene in artemisinin-susceptible *Plasmodium falciparum* parasites from Bougoula-Hameau and Bandiagara, Mali. *American Journal of Tropical Medicine and Hygiene*, 92, 1202–1206.
 25. Phyto AP, Nkhoma S, Stepniewska K, Ashley EA, Nair S, McGready R, Ier Moo C, Al-Saai S, Dondorp AM, Lwin KM, Singhasivanon P, Day NP, White NJ, Anderson TJ, Nosten F. 2012. Emergence of artemisinin-resistant malaria on the western border of Thailand: a longitudinal study. *Lancet*, 379, 1960–1966.
 26. Plowe CV, Djimde A, Bouare M, Doumbo O, Wellems TE. 1995. Pyrimethamine and proguanil resistance-conferring mutations in *Plasmodium falciparum* dihydrofolatereductase: polymerase chain reaction methods for surveillance in Africa. *American Journal of Tropical Medicine and Hygiene*, 52, 565–568.
 27. Shayo A, Mandara CI, Shahada F, Buza J, Lemnge MM, Ishengoma DS. 2014. Therapeutic efficacy and safety of artemether-lumefantrine for the treatment of uncomplicated falciparum malaria in North-Eastern Tanzania. *Malaria Journal*, 13, 376.
 28. Takala-Harrison S, Clark TG, Jacob CG, Cummings MP, Miotto O, Dondorp AM, Fukuda MM, Nosten F, Noedl H, Imwong M, Bethell D, Se Y, Lon C, Tyner SD, Saunders DL, Socheat D, Ariey F, Phyto AP, Starzengruber P, Fuehrer HP, Swoboda P, Stepniewska K, Flegg J, Arze C, Cerqueira GC, Silva JC, Ricklefs SM, Porcella SF, Stephens RM, Adams M, Kenefic LJ, Campino S, Auburn S, MacInnis B, Kwiatkowski DP, Su XZ, White NJ, Ringwald P, Plowe CV. 2013. Genetic loci associated with delayed clearance of *Plasmodium falciparum* following artemisinin treatment in Southeast Asia. *Proceedings of the National Academy of Sciences USA*, 110, 240–245.
 29. Taylor SM, Parobek CM, DeConti DK, Kayentao K, Coulibaly SO, Greenwood BM, Tagbor H, Williams J, Bojang K, Njie F, Desai M, Kariuki S, Gutman J, Mathanga DP, Mårtensson A, Ngasala B, Conrad MD, Rosenthal PJ, Tshetu AK, Moormann AM, Vulule JM, Doumbo OK, TerKuile FO, Meshnick SR, Bailey JA, Juliano JJ. 2015. Absence of putative artemisinin resistance mutations among *Plasmodium falciparum* in Sub-Saharan Africa: a molecular epidemiologic study. *Journal of Infectious Diseases*, 211, 670–679.
 30. Torrentino-Madamet M, Fall V, Benoit N, Camara C, Amalvict R, Fall M, DionneP Fall KB, Nakoulima A, Diatta B, Diemé Y, Ménard D, Wade B, Pradines B. 2014. Limited polymorphisms in k13 gene in *Plasmodium falciparum* isolates from Dakar, Senegal in 2012–2013. *Malaria Journal*, 13, 472.
 31. Tine RCK, Faye B, Sylla K, Ndiaye JL, Ndiaye M, Sow D, Lo AC, Abiola A, Ba MC, Gaye O. 2012. Efficacy and tolerability of a new formulation of artesunate-mefloquine for the treatment of uncomplicated malaria in adult in Senegal: open randomized trial. *Malaria Journal*, 11, 416.
 32. WHO. 2006. WHO guidelines for the treatment of malaria. World Health Organization: Geneva, Switzerland.
 33. Wootton JC, Feng X, Ferdig MT, Cooper RA, Mu J, Baruch DI, Magill AJ, Su XZ. 2002. Genetic diversity and chloroquine

- selective sweeps in *Plasmodium falciparum*. Nature, 418, 320–323.
34. Yadouleton A, N'guessan R, Allagbé H, Asidi A, Boko M, Osse R, Padonou G, Kindé G, Akogbéto M. 2010. The impact of the expansion of urban vegetable farming on malaria transmission in major cities of Benin. Parasites & Vectors, 3, 118.
35. Zwang J, Dorsey G, Mårtensson A, d'Alessandro U, Ndiaye JL, Karema C, Djimde A, Brasseur P, Sirima SB, Olliaro P. 2014. *Plasmodium falciparum* clearance in clinical studies of artesunate-amodiaquine and comparator treatments in sub-Saharan Africa, 1999–2009. Malaria Journal, 13, 114–119.

Cite this article as: Ogouyèmi-Hounto A, Damien G, Deme AB, Ndam NT, Assouhou C, Tchoulin D, Mama A, Hounkpe VO, Moutouama JD, Remoué F, Ndiaye D & Kindé Gazard D: Lack of artemisinin resistance in *Plasmodium falciparum* in northwest Benin after 10 years of use of artemisinin-based combination therapy. Parasite, 2016, 23, 28.



An international open-access, peer-reviewed, online journal publishing high quality papers on all aspects of human and animal parasitology

Reviews, articles and short notes may be submitted. Fields include, but are not limited to: general, medical and veterinary parasitology; morphology, including ultrastructure; parasite systematics, including entomology, acarology, helminthology and protistology, and molecular analyses; molecular biology and biochemistry; immunology of parasitic diseases; host-parasite relationships; ecology and life history of parasites; epidemiology; therapeutics; new diagnostic tools.

All papers in Parasite are published in English. Manuscripts should have a broad interest and must not have been published or submitted elsewhere. No limit is imposed on the length of manuscripts.

Parasite (open-access) continues **Parasite** (print and online editions, 1994-2012) and **Annales de Parasitologie Humaine et Comparée** (1923-1993) and is the official journal of the Société Française de Parasitologie.

Editor-in-Chief:
Jean-Lou Justine, Paris

Submit your manuscript at
<http://parasite.edmgr.com/>